

## COMPANY ANNOUNCEMENT

### Prima Biomed announces resignation of CEO

**Melbourne, Australia. 10 October 2006.** Prima BioMed Ltd (ASX: PRR) advises that Mr Marcus Clark has today informed the Board of his intention to resign as the CEO and as a director with effect from 30 November 2006. After over five years service to the Company, Mr Clark will be accepting a CEO role with another company.

Mr Clark will be actively involved in the completion of the Company's current Phase IIa trial for women with ovarian cancer. Prima is in discussions with Mr Clark for a consultancy while the trial is completed and the results on the final report announced. The final report is expected to be received in the first quarter of 2007.

Mr Eugene Kopp, Executive Chairman, said, "Marcus has delivered substantial value to Prima as its CEO during the development of its bio medical portfolio and more recently with the increasing emphasis on its CVac™ technology. He has been an outstanding CEO during this important period, and leaves Prima well positioned to prosper in the coming years. Having worked together for the past two years I am very sorry that he is leaving us, however I and all Members of the Board thank him for his contributions and wish him all the best for the future."

Mr Kopp will assume the CEO role from the end of November whilst continuing as Executive Chairman. Dr George Mihaly, Chairman of Prima's Scientific Advisory Panel, SAP, (former Managing Director of Clinical Research Organisation, Kendle Pty Ltd), Dr Paul Mitchell (Principal Investigator) and Dr Michael Green (Clinical Oncologist, member of SAP) will be working closely with Mr Kopp to oversee the completion of the current Phase IIa trial and delivery of the final report.

#### For further information:

#### Company Contacts:

Company Enquiries	Eugene Kopp	03 9854 5700
Media Enquiries	Rebecca Wilson	02 9237 2800

#### About Prima Biomed Ltd

Prima Biomed (ASX: PRR) is a biotechnology company based in Melbourne, Australia and is developing technologies in the fields of immunology and cancer immunotherapy originating from the Austin Research Institute in Melbourne now merged with the MacFarlane Burnet Institute of Medical Research and Public Health.

For further information, visit [www.primabiomed.com.au](http://www.primabiomed.com.au)

**Prima BioMed Ltd**, Unit 7/79-83 High St, Kew VIC 3101, AUSTRALIA  
Ph: +61 (0)3 9854 5700 Fax: +61 (0)3 9854 5777  
[www.primabiomed.com.au](http://www.primabiomed.com.au)